首页 > 市场调查报告书 > 医疗设备

重症加护治疗市场规模、份额、成长分析（按药物类别、应用和地区）- 2025-2032 年产业预测

市场调查报告书

商品编码

1847127

重症加护治疗市场规模、份额、成长分析（按药物类别、应用和地区）- 2025-2032 年产业预测

Critical Care Therapeutics Market Size, Share, and Growth Analysis, By Drug Class (Albumin, Prothrombin Complex Concentrates), By Application (Deep Vein Thrombosis, Pulmonary Embolism (PE)), By Region - Industry Forecast 2025-2032

出版日期: 2025年10月13日 | 出版商:

SkyQuest | 英文 175 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计 2023 年全球重症加护治疗市场价值将达到 442 亿美元，从 2024 年的 468.5 亿美元增长到 2032 年的 746.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.0%。

全球重症加护治疗市场的发展受到败血症和呼吸衰竭等危及生命的疾病发病率上升以及加护病房治疗需求日益增长的驱动。对创新药物製剂的需求以及人工智慧与临床决策的整合正在改善治疗效果和患者预后。此外，人口老化和ICU入院人数激增也促进了市场成长。然而，该行业也面临着许多挑战，包括先进疗法的高昂成本限制了低收入地区的患者获得治疗，监管障碍阻碍了产品的普及，以及训练有素的重症加护专业人员的短缺影响了医疗服务的提供。此外，医疗基础设施的地区差异进一步阻碍了重症加护治疗的公平可及，从而影响了市场扩张。

全球重症加护治疗市场驱动因素

全球重症加护治疗市场受到败血症、创伤和呼吸衰竭等严重疾病带来的日益严峻的医疗保健挑战的驱动，导致对加护病房治疗的需求不断增加。促成这项需求的关键因素包括人口老化、ICU入院人数的增加以及对早期疗育重要性的认识的提高。为了满足患者不断变化的需求，医疗保健系统正在加强ICU容量并优化治疗通讯协定。这反映出已开发经济体和新兴经济体都在朝着改善重症患者管理和资源配置的方向转变。

限制全球重症加护治疗市场的因素

阻碍全球推广先进重症加护疗法的一个主要障碍是这些疗法的高成本，尤其是在中低收入国家。医疗保健预算的资金限制严重限制了这些可能挽救生命的疗法的可及性，并对公平医疗造成了重大障碍。医疗保健成本的差异可能会影响区域市场动态，导致不同地区经济状况下的成长轨迹不同。因此，解决这些与成本相关的挑战对于改善全球重症加护疗法的可近性至关重要。

全球重症加护药物市场趋势

全球重症加护治疗市场正经历显着成长，这得益于人工智慧临床决策支援系统的进步。加护病房中人工智慧的应用正在彻底改变诊断和治疗方法，实现预测分析、即时监控和演算法驱动的治疗通讯协定。这使得医疗服务提供者能够更早进行干预，改善患者预后，同时增强患者及其家属的课责。随着医院采用这些创新的人工智慧应用来提高准确性和营运效率，他们对数据驱动临床系统的依赖将推动下一代重症加护治疗的发展，从根本上改变重症医疗服务的模式。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2024年）
主要企业简介
- 公司详情
- 产品系列分析
- 按部门分類的公司份额分析
- 收益同比比较（2022-2024 年）

主要企业简介

Johnson & Johnson（USA）
Roche Holding AG（Switzerland）
Merck & Co., Inc.（USA）
Pfizer Inc.（USA）
AbbVie Inc.（USA）
AstraZeneca plc（UK）
Novartis AG（Switzerland）
Bristol Myers Squibb（USA）
Eli Lilly and Company（USA）
Sanofi SA（France）
Novo Nordisk A/S（Denmark）
GSK plc（UK）
Amgen Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）
Boehringer Ingelheim（Germany）
Gilead Sciences, Inc.（USA）
Bayer AG（Germany）
Baxter International Inc.（USA）
Grifols, SA（Spain）
Cipla Ltd.（India）

结论和建议

简介目录

Product Code: SQMIG35I2449

Global Critical Care Therapeutics Market size was valued at USD 44.2 billion in 2023 and is poised to grow from USD 46.85 billion in 2024 to USD 74.67 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global critical care therapeutics market is driven by the rising incidence of life-threatening conditions such as sepsis and respiratory failure, coupled with an increasing need for intensive care unit therapies. The demand for innovative drug formulations and the integration of artificial intelligence in clinical decision-making are enhancing treatment effectiveness and patient outcomes. Additionally, an aging population and the surge in ICU admissions are contributing to market growth. However, this sector faces challenges, including the high costs of advanced therapeutics limiting access in low-income areas, regulatory hurdles that delay product introductions, and a shortage of trained critical care professionals affecting delivery. Variations in healthcare infrastructure across regions further complicate equal access to critical care interventions, impacting market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Critical Care Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Critical Care Therapeutics Market Segments Analysis

Global Critical Care Therapeutics Market is segmented by Drug Class, Application and region. Based on Drug Class, the market is segmented into Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates, Factor XIII Concentrates and Fibrinogen Concentrates. Based on Application, the market is segmented into Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome, Atrial Fibrillation, Hemodialysis, Coronary Angioplasty and Surgeries. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Critical Care Therapeutics Market

The Global Critical Care Therapeutics market is being propelled by the escalating healthcare challenges posed by critical conditions such as sepsis, trauma, and respiratory failure, resulting in a heightened need for intensive care unit therapies. Key factors contributing to this demand include an aging population, a rise in ICU admissions, and growing awareness surrounding the importance of early intervention. To meet the evolving needs of patients, healthcare systems are enhancing ICU capacities and optimizing treatment protocols, which reflects a broader shift in both developed and emerging economies towards improved critical care management and resource allocation.

Restraints in the Global Critical Care Therapeutics Market

A major obstacle hindering the widespread adoption of advanced critical care therapeutics globally is the prohibitive cost associated with these treatments, especially in low- and middle-income nations. The financial constraints within healthcare budgets significantly restrict access to these potentially lifesaving medications, creating a substantial barrier to equitable care. This disparity in affordability may reshape the regional dynamics of the critical care therapeutics market, resulting in varying growth trajectories based on the economic status of different regions. As a result, addressing these cost-related challenges is crucial for improving access to critical care therapies worldwide.

Market Trends of the Global Critical Care Therapeutics Market

The Global Critical Care Therapeutics market is experiencing significant growth driven by advancements in AI-driven clinical decision support systems. The incorporation of artificial intelligence in intensive care units is revolutionizing diagnostics and treatment methodologies, allowing for predictive analytics, real-time monitoring, and algorithm-driven treatment protocols. This enables healthcare providers to intervene earlier and enhance patient outcomes while fostering accountability to patients and their families. As hospitals adopt these innovative AI applications to achieve precision and operational efficiency, the reliance on data-derived clinical systems is set to propel the development of next-generation critical care therapeutics, fundamentally altering the landscape of critical healthcare delivery.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Critical Care Therapeutics Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Albumin
Prothrombin Complex Concentrates
Antithrombin Concentrates
Factor XIII Concentrates
Fibrinogen Concentrates

Global Critical Care Therapeutics Market Size by Application & CAGR (2025-2032)

Market Overview
Deep Vein Thrombosis
Pulmonary Embolism (PE)
Acute Coronary Syndrome
Atrial Fibrillation
Hemodialysis
Coronary Angioplasty
Surgeries

Global Critical Care Therapeutics Market Size & CAGR (2025-2032)

North America (Drug Class, Application)
- US
- Canada
Europe (Drug Class, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Application)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments